Monopar Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 27, 2023, details the results of the Annual Meeting of Stockholders held by Monopar Therapeutics Inc. on that date. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Wilmette, Illinois.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes and Voting Results
As of the record date (May 1, 2023), 13,222,055.614 shares were entitled to vote. A total of 10,561,932.056 shares were represented at the meeting. Two proposals were submitted and approved:
- Proposal 1: Election of Directors Six directors were elected to serve until the next annual meeting. All nominees received significant "For" votes, with "Broker Non-Votes" totaling 1,651,514.000 for each candidate.
- Proposal 2: Ratification of Auditors Stockholders ratified the selection of BPM LLP as the independent registered public accounting firm for the year ending December 31, 2023. The vote was overwhelmingly in favor (10,529,760.056 For vs. 3,071.000 Against).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. No other matters were submitted to a vote of stockholders.
Key Facts for Investor Verification
- Confirmation that BPM LLP is the appointed auditor for the fiscal year ending December 31, 2023.
- Verification of the six newly elected directors: Christopher M. Starr, Chandler D. Robinson, Michael J. Brown, Raymond W. Anderson, Arthur J. Klausner, and Kim R. Tsuchimoto.
- Review of the Proxy Statement on Schedule 14A for detailed biographical information on the directors and the full context of the voting.